Among the metastatic/unresectable melanoma patients you would historically treat with anti-PD-1 monotherapy, are you now recommending nivolumab/relatlimab instead?

Based on the published RELATIVITY-047 study, the nivo/rela combination leads to a superior median PFS of 10.2 mo (vs 4.6 mo for nivo alone) - both updated at ASCO 2022. At the most recent update at the ASCO 2022, the median survival has not been reached yet for the patients treated with nivo/rela (v...

Most of the patients that I formerly treated with anti-PD-1 alone, I now treat with nivolumab/relatlimab. There are some exceptions - patients with very poor performance status, severe autoimmune disease, etc. Would estimate that I have moved to nivo/rela in about 2/3 of the former anti-PD-1 alone p...